16 completed, 6 terminated, 6 unknown, 5 withdrawn. 33 Phase 2, 4 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 33 | Completed 16, Terminated 6, Unknown 6, Withdrawn 5 |
| Phase 1 | 4 | Completed 3, Unknown 1 |
| Phase 3 | 4 | Completed 1, Terminated 1, Unknown 1, Withdrawn 1 |
Follow SARS-CoV 2: new trials by email Literature Review of SARS-CoV 2 trials Research Report on SARS-CoV 2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Assessment of Oral Lactoferrin as a Safe Antiviral and Immunoregulatory in Treating COVID-19 Disease Lactoferrin (Apolactoferrin), Placebo of excipient(s) will be administered - Corona Virus Infection, Middle East Respiratory Syndrome (MERS) | Phase 2 | Unknown | National Research Centre, Egypt | 516 | 2022-02-01 | 2021-11-15 |
| Trial to Promote Recovery From COVID-19 With Endocrine Therapy Bicalutamide 150 Mg Oral Tablet - COVID-19, SARS-CoV 2 | Phase 2 | Withdrawn | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2021-04-01 | 2021-03-05 | |
| Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19) Oral-B Mouth Sore mouthwash, Crest Pro-Health Multi-Protection mouthwash, CloSYS Ultra Sensitive Rinse mouthwash - COVID-19, SARS-CoV 2 | Phase 2 | Terminated | University of California, San Francisco | 54 | 2021-03-31 | 2023-11-18 |
| Convalescent Plasma for Early Treatment of COVID-19 Convalescent Plasma (anti-SARS-CoV-2 plasma), Control (albumin 5%) - SARS-CoV 2, COVID-19 | Phase 2 | Terminated | Andrew Eisenberger | 223 | 2021-03-12 | 2024-08-28 |
| Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19 ZYESAMI™ (aviptadil acetate), Placebo, Nebulized administration of ZYESAMI™ or Placebo - SARS-CoV 2, COVID | Phase 2 / Phase 3 | Terminated | APR Applied Pharma Research s.a. | 144 | 2021-02-15 | 2023-02-03 |
| P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19 P2Et (Caesalpinia spinosa extract), Placebo - COVID, Coronavirus Infection | Phase 2 / Phase 3 | Unknown | Hospital Universitario San Ignacio | 100 | 2020-09-30 | 2021-08-10 |
| Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19 Oxytocin, Standard of Care - Covid-19, Corona Virus Infection | Phase 2 | Withdrawn | Azienda Ospedaliero-Universitaria di Parma | 2020-09-01 | 2021-01-14 | |
| Favipiravir vs Hydroxychloroquine vs Control in COVID -19 Hydroxychloroquine, Favipiravir, Routine care for COVID-19 patients - SARS-CoV 2, COVID-19 | Phase 2 | Completed | Royal College of Surgeons in Ireland - Medical University of Bahrain | 150 | 2020-08-11 | 2021-10-26 |
| Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19 INO-4800, CELLECTRA® 2000, Saline-sodium citrate (SSC) buffer - Coronavirus Infection, SARS-CoV 2 | Phase 1 / Phase 2 | Completed | International Vaccine Institute | 79 | 2020-07-15 | 2022-07-18 |
| Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (CANADA Trial) 150 ppm Nitric Oxide delivered through LungFit Delivery System, 80 ppm Nitric Oxide delivered through LungFit Delivery System - COVID-19, SARS-CoV 2 | Phase 2 | Withdrawn | Beyond Air Inc. | 2020-07-15 | 2021-01-22 | |
| A Study of Combination Therapies to Treat COVID-19 Infection hydroxychloroquine, Azithromycin, Ritonavir - COVID, COVID-19 | Phase 2 | Withdrawn | ProgenaBiome | 2020-07-01 | 2021-04-08 | |
| Efficacy of Intravenous Melatonin on Mortality in Adult Patients Admitted to the Intensive Care Unit With COVID-19 Melatonin intravenous, Placebo intravenous - COVID-19, SARS-CoV 2 | Phase 2 | Completed | Pharmamel S.L. | 18 | 2020-06-20 | 2021-03-18 |
| The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID) EIDD-2801, Placebo - SARS-CoV 2 | Phase 2 | Completed | Ridgeback Biotherapeutics, LP | 71 | 2020-06-16 | 2023-03-23 |
| GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19) GLS-1200, Placebo - SARS-CoV 2, Infection | Phase 2 | Terminated | GeneOne Life Science, Inc. | 184 | 2020-06-10 | 2025-07-31 |
| Convalescent Plasma to Limit SARS-CoV-2 Associated Complications SARS-CoV-2 convalescent plasma, Plasma from a volunteer donor - SARS-CoV 2 | Phase 2 | Completed | Johns Hopkins University | 1225 | 2020-06-03 | 2023-06-02 |
| Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19 Masitinib, Isoquercetin, Best Supportive Care - SARS-CoV 2, COVID-19 | Phase 2 | Unknown | AB Science | 200 | 2020-06-01 | 2023-02-06 |
| Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation Mavrilimumab, Placebo - COVID 19, SARS-CoV 2 | Phase 2 | Completed | Kristin Hudock | 1 | 2020-05-20 | 2024-12-09 |
| Baricitinib Compared to Standard Therapy in Patients With COVID-19 Baricitinib Oral Tablet - Covid-19, SARS-CoV 2 | Phase 2 | Unknown | Azienda Ospedaliero, Universitaria Pisana | 126 | 2020-05-20 | 2020-05-20 |
| Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation Mavrilimumab, Placebos - COVID 19, SARS-CoV 2 | Phase 2 | Completed | The Cleveland Clinic | 40 | 2020-05-20 | 2021-05-13 |
| CONVALESCENT PLASMA FOR ILL PATIENTS BY COVID-19 convalescent plasma - COVID-19, SARS-CoV 2 | Phase 1 / Phase 2 | Unknown | Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado | 90 | 2020-05-20 | 2020-06-05 |
Showing 20 of 33. Sign in to see all of them.
COVID-19 (26) · Coronavirus Infections (14) · Pneumonia (5) · Respiratory Distress Syndrome (3) · Cytokine Release Syndrome (2) · Pneumonia, Viral (2) · Acute Lung Injury (1) · Convalescence (1) · Dyspnea (1) · Infections (1) · Pharyngeal Diseases (1) · Respiration Disorders (1) · Severe Acute Respiratory Syndrome (1) · Virus Diseases (1)
Coronaviridae Infections (29) · Lung Diseases (29) · Nidovirales Infections (29) · RNA Virus Infections (29) · Respiratory Tract Diseases (29) · Infections (28) · Respiratory Tract Infections (28) · Virus Diseases (28) · Pneumonia, Viral (25) · Pneumonia (23) · Coronavirus Infections (15) · Pathological Conditions, Signs and Symptoms (4) · Pathologic Processes (3) · Respiration Disorders (3) · Inflammation (2)
Hydroxychloroquine (5) · Azithromycin (3) · Standard of Care (3) · COVID-19 Serotherapy (2) · mavrilimumab (2) · Buffers (1) · Calcifediol (1) · Cetylpyridinium (1) · Ethanol (1) · Hydrogen Peroxide (1) · Lactoferrin (1) · Lopinavir (1) · Melatonin (1) · Mouthwashes (1) · Oxytocin (1)
Azienda Ospedaliero, Universitaria Pisana (2) · Maimónides Biomedical Research Institute of Córdoba (2) · The Cleveland Clinic (2) · AB Science (1) · APR Applied Pharma Research s.a. (1) · Andalusian Network for Design and Translation of Advanced Therapies (1) · Andrew Eisenberger (1) · Azienda Ospedaliero-Universitaria di Parma (1) · Banc de Sang i Teixits (1) · Beyond Air Inc. (1) · GeneOne Life Science, Inc. (1) · Hospital Universitario San Ignacio (1) · Instituto de Investigación Hospital Universitario La Paz (1) · Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (1) · International Vaccine Institute (1)
United States (13) · Spain (6) · Italy (4) · France (2) · Bahrain (1) · Brazil (1) · Colombia (1) · Egypt (1) · Germany (1) · India (1) · Israel (1) · Mexico (1) · South Korea (1)
Paul C Cremer, M. D. (2) · Alberto M Borobia, MD, PhD (1) · Alexandra E Kejner, MD (1) · Antoni Torres, MD, PhD (1) · Antonio J Carcas (1) · Asher Tal, MD (1) · Ashwin Balagopal, MD (1) · Catherine H Marshall, MD/MPH (1) · Davey Smith, MD (1) · David J Sullivan, MD (1) · Eu Suk Kim, MD (1) · Francesco Menichetti (1) · Francesco Menichetti, MD (1) · Francesco Pugliese, MD, PhD (1)
PMID 32219428, PMID 33754144, PMID 11023960, PMID 20370679, PMID 25457751, PMID 32032529, PMID 32125452, PMID 32150360, PMID 32228825, PMID 32251638, PMID 32303365, PMID 32650818, PMID 32936949, PMID 33191263, PMID 33273742, PMID 34029377, PMID 34902262, PMID 34981068, PMID 35322077, PMID 35353960, PMID 36048877, PMID 36160152, PMID 36722044, PMID 37117213, PMID 37131659, PMID 38483534, PMID 3898484, PMID 42238425
R01AI152078 (1), U24TR001609 (1), UL1TR003098 (1)